The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of CYP3A5, VEGF-a, and VEGFR2 polymorphisms as markers of sunitinib toxicity.
Cristina Rodriguez de Antona
No relevant relationships to disclose
Enrique Grande Pulido
Consultant or Advisory Role - Pfizer
Lj Leandro-Garcia
No relevant relationships to disclose
Jorge Barriuso
No relevant relationships to disclose
Jaume Capdevila
No relevant relationships to disclose
Paula Jimenez
No relevant relationships to disclose
Beatriz Castelo
No relevant relationships to disclose
Daniel E. Castellano
No relevant relationships to disclose
Federico Longo
No relevant relationships to disclose
Jesus Garcia-Donas
No relevant relationships to disclose